Committee Action
On February 14, 2024, the Subcommittee on Health held a
hearing on H.R. 7406. The title of the hearing was
``Legislative Proposals to Support Patients and Caregivers.''
The Subcommittee received testimony from:
Andy Shih, PhD, Chief Science Officer,
Autism Speaks;
Corey Feist, JD, MBA, Co-Founder and CEO,
Dr. Lorna Breen Heroes' Foundation;
Joanne Pike, DrPH, President and CEO,
Alzheimer's Association;
Gordon Tomaselli, MD, Former President,
American Heart Association; Marilyn and Stanley Katz
Dean, Emeritus and Professor of Medicine, Albert
Einstein College of Medicine; Adjunct Professor of
Medicine, Johns Hopkins University School of Medicine;
Michelle Whitten, President, CEO, and Co-
Founder, Global Down Syndrome Foundation;
Randy Strozyk, President, American Ambulance
Association; and,
Christina Annunziata, MD, PhD, Senior Vice
President of Extramural Discovery Science, American
Cancer Society.
On March 12, 2024, the Subcommittee on Health met in open
markup session and forwarded H.R. 7406, as amended, to the full
Committee by a voice vote.
On March 20, 2024, the full Committee on Energy and
Commerce met in open markup session and ordered H.R. 7406, as
amended, favorably reported to the House by a record vote of 46
yeas and 0 nays.
Congressional Budget Office Estimate
Pursuant to clause 3(c)(3) of rule XIII, at the time this
report was filed, the cost estimate prepared by the Director of
the Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974 was not available.
Federal Mandates Statement
The Committee adopts as its own the estimate of Federal
mandates prepared by the Director of the Congressional Budget
Office pursuant to section 423 of the Unfunded Mandates Reform
Act.
Statement of General Performance Goals and Objectives
Pursuant to clause 3(c)(4) of rule XIII, the general
performance goal or objective of this legislation is to
establish a research program focused on investigating
comorbidities of Down syndrome, with the goal of utilizing
research findings to improve the quality of life for people
with Down syndrome.
Duplication of Federal Programs
Pursuant to clause 3(c)(5) of rule XIII, no provision of
H.R. 7406 is known to be duplicative of another Federal
program, including any program that was included in a report to
Congress pursuant to section 21 of Public Law 111-139 or the
most recent Catalog of Federal Domestic Assistance.
Related Committee and Subcommittee Hearings
Pursuant to clause 3(c)(6) of rule XIII, the following
related hearing was used to develop or consider H.R. 7406:
On February 14, 2024, the Subcommittee on
Health held a hearing on H.R. 7406. The title of the
hearing was ``Legislative Proposals to Support Patients
and Caregivers.'' The Subcommittee received testimony
from:
Andy Shih, PhD, Chief Science
Officer, Autism Speaks;
Corey Feist, JD, MBA, Co-Founder
and CEO, Dr. Lorna Breen Heroes' Foundation;
Joanne Pike, DrPH, President and
CEO, Alzheimer's Association;
Gordon Tomaselli, MD, Former
President, American Heart Association; Marilyn
and Stanley Katz Dean, Emeritus and Professor
of Medicine, Albert Einstein College of
Medicine; Adjunct Professor of Medicine, Johns
Hopkins University School of Medicine;
Michelle Whitten, President, CEO,
and Co-Founder, Global Down Syndrome
Foundation;
Randy Strozyk, President,
American Ambulance Association; and,
Christina Annunziata, MD, PhD,
Senior Vice President of Extramural Discovery
Science, American Cancer Society.
Committee Cost Estimate
Pursuant to clause 3(d)(1) of rule XIII, the Committee
adopts as its own the cost estimate prepared by the Director of
the Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974. At the time this report was
filed, the estimate was not available.
Earmark, Limited Tax Benefits, and Limited Tariff Benefits
Pursuant to clause 9(e), 9(f), and 9(g) of rule XXI, the
Committee finds that H.R. 7406 contains no earmarks, limited
tax benefits, or limited tariff benefits.
Advisory Committee Statement
No advisory committees within the meaning of section 5(b)
of the Federal Advisory Committee Act were created by this
legislation.
Applicability to Legislative Branch
The Committee finds that the legislation does not relate to
the terms and conditions of employment or access to public
services or accommodations within the meaning of section
102(b)(3) of the Congressional Accountability Act.
Section-by-Section Analysis of the Legislation
Section 1. Short title
Section 1 provides that the Act may be cited as the
``DeOndra Dixon INCLUDE Project Act of 2024''.
Section 2. Down syndrome research
Section 2 directs the Secretary of the Department of Health
and Human Services, acting through the Director of the National
Institutes of Health to establish and oversee the
implementation of a research program focused on Down syndrome.
This section also specifies certain topics that should be
investigated within the research program, as well as implements
Congressional reporting requirements.
Changes in Existing Law Made by the Bill, as Reported
In compliance with clause 3(e) of rule XIII of the Rules of
the House of Representatives, changes in existing law made by
the bill, as reported, are shown as follows (new matter is
printed in italics and existing law in which no change is
proposed is shown in roman):
PUBLIC HEALTH SERVICE ACT
* * * * * * *
TITLE IV--NATIONAL RESEARCH INSTITUTES
Part A--National Institutes of Health
* * * * * * *
SEC. 404P. DOWN SYNDROME RESEARCH.
(a) In General.--The Secretary, acting through the Office of
the Director of NIH, and in consultation with other Federal
agencies and partners, shall carry out a program of research,
training, and investigation related to Down syndrome to be
known as the ``INvestigation of Co-occurring conditions across
the Lifespan to Understand Down syndromE Project'' or the
``INCLUDE Project''.
(b) Program Elements.--The program under subsection (a) shall
include research, training, and investigation related to--
(1) high-risk, high reward basic science studies of
the effects of chromosome 21 on human development and
health;
(2) assembling and maintaining a large study
population of individuals with Down syndrome;
(3) expanding the number of clinical trials that are
inclusive of, or expressly for, individuals with Down
syndrome, including novel biomedical and
pharmacological interventions and other therapies
designed to promote or enhance activities of daily
living;
(4) the biological mechanisms in individuals with
Down syndrome responsible for structural and functional
anomalies in cells, tissues, and organs, cognitive and
behavioral dysfunction, and stunted growth;
(5) the identification of biomarkers for the
detection of risk factors, diagnosis, and customized
interventions and treatments for conditions co-
occurring with Down syndrome;
(6) why several co-occurring conditions, such as
Alzheimer's Disease and autoimmunity, are prevalent in
individuals with Down syndrome and how such conditions
can be treated concurrently with Down syndrome; and
(7) improving the quality of life of individuals with
Down syndrome and their families.
(c) Coordination; Prioritizing Nonduplicative Research.--The
Secretary shall ensure that--
(1) the programs and activities of the institutes,
centers, agencies, and offices of the National
Institutes of Health relating to Down Syndrome and co-
occurring conditions are coordinated, including through
the Division of Program Coordination, Planning, and
Strategic Initiatives under sections 402(b)(7) and
402A(c); and
(2) such institutes, centers, agencies, and offices
prioritize, as appropriate, Down syndrome research that
does not duplicate existing research activities of the
National Institutes of Health.
(d) Technical Assistance.--The Secretary shall provide
technical assistance to grantees and other involved entities,
as appropriate, for carrying out activities pursuant to this
section.
(e) Biennial Reports to Congress.--
(1) In general.--The Secretary shall submit, on a
biennial basis, to the Committee on Energy and Commerce
and the Subcommittee on Labor, Health and Human
Services, Education of the Committee on Appropriations
of the House of Representatives and the Committee on
Health, Education, Labor, and Pensions and the
Subcommittee on Labor, Health and Human Services,
Education, and Related Agencies of the Committee on
Appropriations of the Senate, a report that catalogs
the research conducted or supported under this section.
(2) Contents.--Each report under paragraph (1) shall
include--
(A) identification of the institute, center,
agency, office, or entity involved;
(B) a statement of whether the research is or
was being carried out directly by the
institute, center, agency, office, or entity or
by multiple institutes, centers, agencies,
offices, or entities; and
(C) identification of any resulting real
world evidence that is or may be used for
clinical research and medical care for patients
with Down syndrome.
(f) Authorization of Appropriations.--
(1) In general.--To carry out this section, there is
authorized to be appropriated $90,000,000 for each of
fiscal years 2025 through 2029.
(2) Supplement, not supplant.--Funds appropriated to
carry out this section shall be used to supplement, not
supplant, other funds allocated by the National
Institutes of Health for research and other activities
relating to Down syndrome.
* * * * * * *
[all]